Monday, March 27, 2023 | Back issues
Courthouse News Service Courthouse News Service

Diabetes drugs

SAN FRANCISCO — A federal court in California granted final approval to a nearly $454 million settlement in an antitrust action alleging manufacturers of a type 2 diabetes drug engaged in a “reverse-payment scheme and agreed not to compete with each other by delaying the introduction of a generic version of the drug for several years.”

Read the order here.  

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.